Abstract: Provided herein are novel methods for increasing T cell effector function in a T cell populations, as well as methods for increasing T cell effector function in a subject. The methods include contacting a T cell in a T cell population with a pharmaceutical composition comprising an antagonist of histone deacetylase 3 (HDAC3). Also provided herein are methods for identifying a compound that modulates HDAC3 activity in cytotoxic T cells.

Abstract: Compositions and methods are disclosed for treating erectile dysfunction in a patient. A sample of whole blood is collected from the patient, and a sample of platelet-rich plasma (PRP) is extracted from the sample of whole blood. The sample of PRP is mixed with a predetermined amount of botulinum toxin (BTX) to form a PRP/BTX mixture, which is then injected into a region of human tissue of the patient.

Abstract: Disclosed is a composition including: an isolated in vitro pre-conditioned population of adult bone marrow derived mesenchymal stem cells (BMSCs), wherein the BMSCs express neuronal markers, and wherein the neuronal markers are PGP9.5, NSE, Tuj1, HuC/D and neuronal nitric oxide synthase (nNOS). Methods of preparing the BMSCs are also provided. In addition, the present disclosure is directed to a method of treating an enteric nervous system-related disorder including: administering to a subject in need thereof a pharmaceutical composition including the in vitro pre-conditioned BMSC population and a pharmaceutically acceptable carrier.

Abstract: Methods for providing allogeneic, immune-tolerant and virus-resistant umbilical cord blood cells are provided. Compositions and methods for treating a disease or condition in a subject by transplantation of allogeneic, immune-tolerant, and virus-resistant umbilical cord blood cells are provided. PCR-based methods for identifying donor cord blood having a CCR5 ?32 genotype conferring HIV-resistance are provided.

Abstract: A method of treating a subject in need of a non-syngeneic cell or tissue graft is disclosed. The methods comprising: (a) transplanting into a subject a dose of T cell depleted immature hematopoetic cells, wherein the T cell depleted immature hematopoetic cells comprise less than 5×105 CD3+ T cells per kilogram body weight of the subject, and wherein the dose comprises at least about 5×106 CD34+ cells per kilogram body weight of the subject, and wherein the T cell depleted immature hematopoetic cells are obtained by separating the T cells from from the immature hematopoetic cells by magnetic cell sorting, and (b) administering to the subject a therapeutically effective amount of cyclophosphamide, wherein the therapeutically effective amount comprises 25-200 mg per body weight, thereby treating the subject.

Abstract: Methods and protocols of harvesting and processing of Porifera species, specifically sponges, and more specifically fresh water species of Genus Spongilla; testing and storing of the processed Spongilla powder; and manufacturing and packaging of Spongilla-based therapeutic compositions for treating and preventing skin diseases are disclosed. Treatable skin conditions and diseases include without limitation acne vulgaris, rosacea, seborrheic dermatitis, psoriasis, photo-aging and actinic keratosis, acne vulgaris, psoriasis, photo-aging, wounds, scars, and eczema (atopic dermatitis).

Abstract: The invention relates to a Coleoptera powder for using in the treatment of vibriosis, which particularly affects the white shrimp.

Abstract: The invention relates to a method for the preparation of dry formulations of dairy probiotic bacteria using a combination of different polymers. The said formulations having increased viability during processing, storage and upon transfers to the rumen of the dairy animals. Further said formulations having high tolerance to lactate and acetate in the rumen of dairy animals.

Abstract: The present invention provides a lactobacillus strain-containing pharmaceutical composition and food composition for improving of kidney disease and inhibiting inflammation, which comprises an isolated lactic acid bacteria strain. The isolated lactic acid bacteria strain is at least one selected from a group including BLI-02 strain, CGMCC No. 15212, Bifidobacterium longum subsp. infantis, TYCA06 strain, CGMCC No. 15210, Lactobacillus acidophilus, VDD088 strain, CGMCC No. 15211, Bifidobacterium bifidum, and combinations thereof.

Abstract: The present disclosure relates to compositions and methods for treating autism spectrum disorder (ASD) by restoring an ASD patient's gut microbiota. These methods can be used with ASD patient with or without ongoing gastrointestinal symptoms. Provided here is a method for ASD treatment in a subject in need thereof comprising or consisting essentially of administering a therapeutic composition comprising a fecal microbe or a fecal microbiota preparation to the subject. Also provided here is a method comprises administering an antibiotic to a human subject; subjecting the human subject to a bowel cleanse; and administering purified fecal microbiota to the human subject. Further provided are evaluation and quantitative characterization of patient symptom improvements upon treatment described here.

Abstract: The present invention relates to at least one probiotic strain of Lactobacillus for use in a subject for the prevention and/or treatment of celiac disease autoimmunity (CDA), or for use in the prevention and/or treatment of celiac disease (CD). A preferred composition for use according to the invention is a composition comprising a combination of Lactobacillus paracasei and Lactobacillus plantarum, especially L. paracasei 8700:2 (DSM 13434) in combination with L. plantarum HEAL 9 (DSM 15312).

Abstract: The present invention relates to a medicament for preventing and/or treating cognitive impairment and/or a neurodegenerative disease with accumulation of a prionoid, comprising a Sendai virus envelope as an active ingredient and combined application of the medicament and an immune checkpoint inhibitor.

Abstract: The present invention relates to an anticancer composition comprising a recombinant adenovirus which expresses degradation factors for the extracellular matrix. The recombinant adenovirus according to the present invention exhibits an excellent anti-tumor effect by remarkably reducing the main structural components of the extracellular matrix in a tumor tissue, including collagen I, collagen III, fibronectin, elastin, and the like and highly expressing a therapeutic gene selectively only in tumor cells through viral proliferation. Particularly, when administered in combination with therapeutic materials, such as anticancer agents or immune checkpoint inhibitors, the recombinant adenovirus significantly increases the diffusion and distribution of the co-administered therapeutic materials in tumor tissues while allowing the exertion of the preexisting anticancer effects, thereby further improving an anti-cancer effect.

Abstract: A process includes rupturing plant cells of cannabis by freeze-drying the cannabis at a temperature below 0° C. in order to expose or release one or more chemicals including at least cannabinoids in the plant cells of the cannabis, after rupturing the cannabis plant cells, extracting the one or more chemicals including at least cannabinoids from the cannabis by pressurizing the cannabis in a pressure vessel with along with a solvent, the solvent dissolving the one or more chemicals including at least cannabinoids, followed by depressurizing the cannabis in the pressure vessel, where the depressurizing precipitates the one or more chemicals including at least cannabinoids out of the solvent, and then isolating the one or more chemicals including at least cannabinoids that precipitated from the solvent.

Abstract: The invention relates to skin care compositions comprising an ethanol extract obtained from the leaves and/or stems of Arthrocnemum macrostachyum and/or Tetraena sp. cf. mandavillei. In addition, the invention relates to methods for treating a skin condition, reducing the risk of developing a skin condition, for treating wounds, for reducing and/or delaying the effects of aging of skin, and/or for treating and/or reducing inflammation of skin by administration of skin care compositions of the invention.

Abstract: The present invention relates to new compositions suitable for use in the treatment of articular disorders (or conditions), processes for preparing said compositions and use of said compositions in therapeutic treatments of articular disorders.

Abstract: The invention relates to a (i) Vitamin A, a reaction product, a metabolite or a precursor of it and (ii) a plant extract of chamomile or an active component thereof, preferably for use in the treatment of cancer. The inventive composition may be provided as a medicament or a pharmaceutical composition. The at least one Chamomilla plant typically contained in the inventive compositions preferably comprises Matricaria recutita, more preferably fibres tubiformis of Matricaria recutita. Esters of Retinol typically contained in the inventive compositions typically comprise e.g. Retinyl acetate and a plant extract from the plant Matricaria recutita.

Abstract: The invention relates to therapeutic compositions, solid oral dosage forms, and methods for treating, preventing, or alleviating lower urinary tract symptoms (LUTS), benign prostatic hyperplasia (BPH), erectile dysfunction (ED), urinary incontinence, bladder obstruction, overactive bladder (OAB), underactive bladder, interstitial cystitis, prostatitis, bladder and prostate inflammation, prostate fibrosis or pelvic pain. The therapeutic compositions can comprise cranberry powder enriched in cranberry seeds or cranberry seed meal.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating cancer, a food composition for enhancing immune functions, and a pharmaceutical composition for preventing or treating cachexia. The composition of the present invention provides effects of further inhibiting the growth of tumors, increasing immunological activity, and suppressing cachexia caused by tumors. In addition, the composition of the present invention can obtain a synergistic effect when co-administered with an existing anticancer drug.

Abstract: The present invention relates to a use of a banana stamen extract for promoting hair growth. The banana stamen extract according to the present invention promotes gene expression of VEGF and IGF1 to enhance the proliferation level of hair follicles, so that the density of hairs grown is increased. In addition, the banana stamen extract also inhibits gene expression of SRD5A1, SRDA2 and AR to decrease hair loss, and promote the gene expression of KROX20 so as to significantly enhance hair growth.

Abstract: A method of fabricating an electronic power module by additive manufacturing, the electronic module including a substrate having an electrically insulating plate presenting opposite first and second faces, with a first metal layer arranged directly on the first face of the insulating plate, and a second metal layer arranged directly on the second face of the insulating plate. At least one of the metal layers is made by a step of depositing a thin layer of copper and a step of annealing the metal layer, and the method further includes a step of forming at least one thermomechanical transition layer on at least one of the first and second metal layers, the at least one thermomechanical transition layer including a material presenting a coefficient of thermal expansion that is less than that of the metal of the metal layer.

Abstract: The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.

Abstract: A peptide consisting of an amino acid sequence of GPPGPAG (SEQ ID NO: 1) is disclosed. According to the present invention, a novel compound for improving memory disorder is provided.

Abstract: The present invention provides compositions and methods for treating or preventing environmental enteropathy and associated intestinal damage. The compositions comprise Larazotide or Larazotide derivatives.

Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.

Abstract: Methods for preventing esophageal stricture following an endoscopic resection procedure in a subject are provided. A solution having a pH level of about 3.5 and including a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under esophageal conditions to provide prevention of esophageal stricture may be introduced to a target site.

Abstract: The present invention relates to the treatment and prevention of cancer. The present invention relates to vaccines comprising solubilized components of cancer cells or cancer-associated cells. Moreover, the present invention also relates to methods of producing vaccines from biological samples comprising cancer cells or cancer-associated cells and using said vaccines for the treatment or prevention of cancer in subjects. The present invention also relates to methods of producing vaccines, in particular, autologous vaccines. The present invention also relates to therapeutic uses of mesenchymal stem cells and to methods of treatment and or prevention that comprise administering mesenchymal stem cells to a subject. The present invention also relates to methods of enhancing the efficacy of vaccines and methods for the treatment and prevention of cancer, and to compositions and kits suitable for use in the methods.

Abstract: Described herein are stein cells and related factors for treating degenerative and inflammatory disorders of lung tissue.

Abstract: Methods and compositions using a nucleic acid molecule encoding an atonal-associated factor in combination with a co-transcription factor and/or inhibitor of a gene silencing complex to change the sensory perception of an animal are described.

Abstract: The present disclosure describes the fusogenic activity of the Myomaker protein. This polypeptide, when expressed in non-muscle cells, is able to drive fusion of the cell with a muscle cell, but not with other non-muscle cells. The use of this protein and cell expressing it in the delivery of exogenous genetic material to muscle cells also is described.

Abstract: In certain aspects, disclosed herein are novel compositions and methods related to either the enhancement or inhibition of erythropoiesis that are useful, for example, in the treatment of anemia or erythrocytosis.

Abstract: The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidemia, obesity, and fatty liver.

Abstract: Provided is a method of treating coronary artery disease in a mammal, comprising administering to a region of the heart of the mammal (a) a first vector encoding one or more angiogenic proteins which induce vascularization in the heart of the mammal, and (b) a second vector encoding one or more cardio-differentiating transcription factors which induce the production of induced cardiomyocytes (iCM) in the heart of the mammal, whereby the coronary artery disease in the mammal is treated. In a preferred embodiment, the first vector is an adenoviral vector encoding VEGF and the second vector is a lentiviral vector encoding Gata4, Mef2c, and Tbx5 (GMT).

Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.

Abstract: The present disclosure relates to glucagon-like peptide-1 receptor (GLP-1R) agonists and methods of treating or preventing allergic inflammation and/or methods of treating or preventing respiratory syncytial virus (RSV) infection.

Abstract: Methods and compositions for treating a patient for a condition selected from the group consisting of obesity or diabetes, or a combination thereof, are provided herein. A method includes administering to the patient a compound including a histone acetyltransferase inhibitor (iHAT), or an IgF-1 derivative, and a pharmaceutically acceptable carrier.

Abstract: A histidine-free composition comprising: a high purity factor VIII (r-factor VIII); arginine and/or sucrose; a surface-active agent to prevent or at least inhibit surface adsorption of factor VIII; an amount of calcium chloride for specific stabilization of factor VIII.

Abstract: Described are compositions comprising ?-galactosidase A enzymes with unique carbohydrate profiles, as well as methods for manufacturing and purifying such enzymes. Also described methods of treating, preventing, and/or ameliorating Fabry Disease by administering such enzymes to a subject in need thereof. Also described are compositions comprising migalastat in combination with such ?-galactosidase A enzymes.

Abstract: Compositions and methods are described for the delivery of a fully human-glycosylated (HuGly) ?-L-iduronidase (IDUA) to the cerebrospinal fluid of the central nervous system (CNS) of a human subject diagnosed with mucopolysaccharidosis I (MPS I).

Abstract: Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols.

Abstract: The disclosure provides compositions and methods useful for treating glaucoma. In particular, the invention provides an adeno-associated viral (AAV)-mediated gene therapy for glaucoma in which transduced cells of the eye secrete a therapeutic protein (for example, a matrix metalloproteinase) resulting in remodeling of the extracellular matrix of the trabecular meshwork of said eye.

Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.

Abstract: The purpose of the present invention is to provide a novel medicine that is effective in treating cerebral infarction. The present invention provides a pharmaceutical composition that contains a peptidyl-prolyl cis-trans isomerase B (PPIB) protein, a nucleic acid encoding the PPIB protein, or a cell that secretes the PPIB protein.

Abstract: A vaccine against TPR's ligand binding domain, namely the C-terminus of the second extracellular loop (C-EL2), inhibits platelet activation and thrombus formation, without exerting any effects on hemostasis.

Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

Abstract: The present invention relates i.a. to a method for reducing the concentration of skatole and/or indole in an animal comprising administering to said animal an effective amount of an immunogenic composition comprising Lawsonia intracellularis antigen. Therefore, the present invention also relates to methods for reducing pork odor or boar taint.

Abstract: Provided are compositions and methods for use in prophylaxis of puerperal metritis and improving reproductive function of ruminants. The methods and compositions are for subcutaneous administration and are provided as veterinary compositions and as articles of manufacture. The veterinary composition can contain whole cells selected from whole cells of Escherichia coli (E. coli), Trueperella pyogenes (T. pyogenes), Fusobacterium necrophorum (F. necrophorum) and combinations thereof; and/or proteins selected from F. necrophorum leukotoxin (LKT), E. coli type 1 fimbrial adhesin (FimH), T. pyogenes pyolysin (PLO), and all combinations of the whole cells and the proteins.

Abstract: The present disclosure relates to compositions and methods for coupling an antigen to an adjuvant, immunogenic compositions and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.

Abstract: The present invention relates to polypeptides suitable for protection against and diagnosis of the conditions caused by flavivirus infections. More specifically, the invention concerns subunits of the zika virus envelope glycoprotein E secreted as mature recombinantly produced proteins from eucaryotic cells, such as from insect cells. Additional viral proteins or subunits, also produced in this way, provide additional active ingredients. These protein subunits, alone or in combination including combination with additional viral-derived peptides are protective against infection by flavivirus, such as zika virus, raise antibodies useful in immunization, and are useful in diagnosis of infection by the virus.

Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.